231 related articles for article (PubMed ID: 21411412)
1. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
[No Abstract] [Full Text] [Related]
2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
3. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
4. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
5. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
6. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
Ubriani R; Van Voorhees AS
Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
[No Abstract] [Full Text] [Related]
7. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
Hernández MV; Ruiz-Esquide V; Gómez-Caballero ME; Gómez-Puerta JA; Cañete JD; Sanmartí R
Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
[No Abstract] [Full Text] [Related]
8. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
[TBL] [Abstract][Full Text] [Related]
9. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
[No Abstract] [Full Text] [Related]
10. New-onset psoriasis associated with etanercept therapy.
Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
[No Abstract] [Full Text] [Related]
11. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
12. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
Modesti V; Ramonda R; Ortolan A; Lorenzin M; Lo Nigro A; Frallonardo P; Oliviero F; Campana C; Punzi L
Scand J Rheumatol; 2012; 41(6):490-1. PubMed ID: 22985209
[No Abstract] [Full Text] [Related]
13. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
14. [Biological treatment of ankylosing spondylitis].
Freiesleben S; Schou M
Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
[TBL] [Abstract][Full Text] [Related]
15. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.
Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR
Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791
[TBL] [Abstract][Full Text] [Related]
16. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
Berg PA
Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
[No Abstract] [Full Text] [Related]
17. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
18. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
Braun J
Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
[No Abstract] [Full Text] [Related]
19. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.
Savastano M; Marioni G; Giacomelli L; Ramonda R; Ferraro SM; Punzi L
B-ENT; 2010; 6(3):183-8. PubMed ID: 21090160
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]